Dual Antiplatelet Therapy Duration: A Review of Current Available Evidence

Ioannis Mastoris1, Priyanka Maria Mathias2, George D Dangas3

  • 1Icahn School of Medicine, Mount Sinai Hospital, New York, New York; Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, New York.

Clinical Therapeutics
|March 20, 2016
PubMed

Insights

The optimal duration of dual-antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) is not definitively established. Individual patient factors and clinical judgment are crucial for determining DAPT treatment length.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Pharmacology

Background:

  • Dual-antiplatelet therapy (DAPT) is standard after percutaneous coronary intervention (PCI) to prevent thrombotic events.
  • Optimal DAPT duration following PCI remains an area of active research and clinical debate.

Purpose of the Study:

  • To review randomized clinical trials (RCTs), pooled analyses, and meta-analyses on DAPT duration after PCI.
  • To provide recommendations for optimal DAPT duration based on patient and procedural profiles.

Main Methods:

  • Extensive literature search across multiple databases (MEDLINE, Scopus, Cochrane Library).
  • Inclusion of RCTs, meta-analyses, and observational studies without language or date restrictions.
  • Exclusion of irrelevant studies not pertaining to DAPT duration after PCI.

Main Results:

  • Identified 10 RCTs comparing DAPT durations and 3 meta-analyses.
  • Numerous observational studies provided additional insights into DAPT duration.
  • No conclusive evidence was found to mandate a specific DAPT duration post-PCI.

Conclusions:

  • No definitive evidence dictates mandatory DAPT duration after PCI.
  • Specific patient groups (e.g., diabetics, those on anticoagulation) require tailored DAPT regimens.
  • Individualized clinical judgment considering patient, procedural, and stent-related factors is essential.
Abstract

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
398
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
10.6K
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
545
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
459
Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration01:23

Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration

Drug elimination from the body primarily occurs through metabolic and excretion pathways. Hepatic metabolism transforms lipophilic drugs into hydrophilic forms for excretion, typically via enzymatic processes classified as phase I (modification) and phase II (conjugation). Renal excretion eliminates drugs and metabolites through filtration and secretion in the kidneys. Impairment in liver or kidney function can hinder these processes, delaying drug clearance and extending the drug’s...
86